Herbert Loong: 6 versus 3 years of adjuvant imatinib in high risk GISTs by Jean-Yves Blay et al.
Herbert Loong shared on LinkedIn:
“Congrats Jean-Yves Blay and colleagues of French Sarcoma Group for completing study of 6 versus 3 years of adjuvant imatinib in patients with GISTs.
Presented at ESMO – European Society for Medical Oncology AACR Journals virtual plenary over last 2 days with specific discussions from APAC discussants as well!
Chen Recordings available on OncologyPro!”
Source: Herbert Loong/LinkedIn
Dr. Herbert H. F. Loong is an Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK), with additional roles as Deputy Medical Director of the Phase 1 Clinical Trials Centre and founder of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team. Dr. Loong has co-founded key organizations like the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC). His involvement in international oncology bodies, including ASCO and IASLC, underscores his commitment to advancing cancer research and treatment on a global scale.
